Chronic pain is one of the most underestimated healthcare problems in the world today, causing major consequences for the quality of life of the sufferer and a major burden on the healthcare system and society. One in five people in the general adult population – 150 million Europeans – have chronic pain, more than heart disease, cancer and diabetes combined. With an aging population, the problem is likely to be felt even stronger in the years to come. Conventional treatment options offer only a partial response to the problem, with many people continuing to suffer with their severe chronic pain on a daily basis despite receiving several treatments. Consequently, there is a true and significant unmet need in optimal pain management.
SzeleSTIM offers an innovative patient-centred, non-invasive pain management system based on electrical stimulation of the vagus nerve in the ear. SzeleSTIM’s wearable device AuriMod helps to avoid conventional pain management drugs’ side effects and preventing complications including chronic wounds and consequent amputations. Its unique biofeedback-controlled algorithm uses patient real-time physiological data for automatically adjusting the therapy. In this way, SzeleSTIM paves the way for truly individualized therapy, based on the patient’s individual condition and dynamic needs. In addition to pain management, other potential future applications of the AuriMod device include vascular diseases such as Peripheral Arterial Disease (PAD), and also migraine, or autoimmune diseases.